Stocks rally Friday after a seemingly ‘goldilocks’ jobs report, with consumer-leveraged stocks among the biggest winners. Plus, an exclusive with the EISAI US CEO - which worked with Biogen on the FDA’s approval of its Alzheimer’s treatment that slowed cognitive decline in a clinical trial.
Yesterday
Qualcomm’s New Chip… And Opportunities Abroad 10/27/25
Shares of Qualcomm surging as the chipmaker announces a new AI accelerator chip. How it positions the company in the data center duels, and the semi surge its bringing to the rest of the space. Plus Japan, Argentina, and China all ticking higher as positive trade headlines move m ... Show More
43m 44s
Oct 23
Intel Reports Results… And Quantum Leaps As U.S. Eyes Next Equity Stake 10/23/25
Intel on the move as results cross the wires, as memory chip stocks rally on reports of higher prices. Plus, how one derivatives strategist is navigating AI volatility ahead of Mag7 earnings, the jump in crude oil as new sanctions on Russia comes into focus, and the leap in quant ... Show More
43m 50s
Dec 2021
Pfizer & BioNTech Share Results on Boosters as Job Openings Near All-Time High
DB-Dec08,2021:With markets easing on Omicron fears this week and assets across the board beginning to recover from last week’s drawdowns, Pfizer and BioNTech both announced today the initial findings of the effectiveness of their boosters against the Omicron variant, demonstratin ... Show More
37m 22s
Aug 2021
The Chinese Stock Rally and the Cathie Wood Effect, Mandates and the Reopening Trade After Full Approval of Pfizer's COVID Vaccine, Boeing Faces New Scrutiny, Tim Cook's Decade as CEO of Apple, and t
Carl Quintanilla, Jim Cramer and David Faber explored the reasons behind a big rally in shares of China-based companies. One of the catalysts: Cathie Wood's Ark Invest buying almost 165,000 shares of JD.com. The reopening trade very much in focus one day after the FDA fully appro ... Show More
44m 6s
Mar 2023
How Well Does A New Alzheimer's Drug Work For Those Most At Risk?
A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ... Show More
13m 46s
Aug 2021
Disney Beats the Street and Leads the Stock Market to Record Highs, the FDA's COVID Booster Shot Authorization and Companies’ Approaches to Vaccinations, What Airbnb and DoorDash’s Results Tell Us Abo
Carl Quintanilla, Morgan Brennan and Mike Santoli led off the show with Disney, whose better-than-expected quarterly results drove the stock higher, leading the Dow and S&P 500 to new record intraday highs. The anchors reacted to what Disney CEO Bob Chapek's told CNBC about Disne ... Show More
43m 46s
Aug 2021
Fed Chair Powell and Inflation Watch, Challenges for The Reopening Trade, The FDA and a Third Booster Shot, More Companies Revise Return to Work Plans, Micron As a "Red" Chip, Credit Card Spending Dat
The morning after the Dow and S&P 500 posted record closing highs, Carl Quintanilla, Jim Cramer and David Faber led of the show with new wholesale inflation data: Producer prices for July coming in hotter than expected, rising one percent from the previous month and up 7.8-percen ... Show More
43m 28s
Jan 2022
Tech Sector Extends Losses, Growth Stocks' "Shellacking," the White House Doubles Up on Pfizer's COVID Pill and France's Macron Says "Piss Off" the Unvaccinated.
Carl Quintanilla, Jim Cramer and David Faber discussed tech stocks extending losses from Tuesday's sell-off in light of rising rates. David highlighted the "shellacking" growth stocks have taken as of late, including Shopify, business software provider HubSpot, plus Salesforce an ... Show More
43m 17s
Nov 2020
COVID-19 Worries Pressure Stocks, Presidential Transition: The Business Community Speaks Out, Exclusive With Media Mogul John Malone, And GoodRx Co-CEO Reacts To Amazon Pharmacy
Carl Quintanilla, Jim Cramer and David Faber discussed the Dow and S&P 500 extending Wednesday's losses on worries about COVID-19, with deaths surpassing 250,000 in the U.S. -- and therecent surge in cases resulting in lockdowns. The anchors also took a closer look at a push by b ... Show More
42m 38s